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group, model+EA group, and model+ﬂuoxetine group. Use
biotin-labeled protein chip technology to detect the protein
expression of TGF-3, FS L-1 and IL-1 of hippocampus.
Results:Compared to the control group, the protein expres-
sion of TGF-3 in the model group were down-regulated
(fold change= 0.48), FSL-1 and IL-1 were up-regulated (fold
change=1.27; 1.57). Compared to the model group, the pro-
tein expression of TGF-3were up-regulating in themodel+EA
group (fold change=1.61) and the model+ﬂuoxetine group
(fold change=1.60), while the protein expression of FSL-1
and IL-1 were both down-regulating in the model+EA group
(fold change=0.75; 0.60) and the model+ﬂuoxetine group (fold
change=0.67; 0.54).
Conclusion: The results showed that EA improved signiﬁ-
cantly dysfunction of hippocampus by facilitating hippocam-
pal neuron differentiation and preventing them apoptosis
and inﬂammation, which was as effective as ﬂuoxetine.
Consequently, EA is a useful antidepressant treatment for
depression model rats.
Contact: Xuhui Zhang, rabbit zxh@163.com
http://dx.doi.org/10.1016/j.imr.2015.04.307
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Purpose: Chinese herbal medicine (CHM) is often pre-
scribed as an adjunct to guideline recommended bronchodila-
tors in the management of chronic obstructive pulmonary
disease (COPD). We performed a systematic review and net-
work meta- analysis (NMA) to evaluate the comparative
effectiveness of CHM plus bronchodilators, versus bron-
chodilators alone.
Methods: Fifteen randomized controlled trials withmoder-
ate risk of bias were included.
Results: Results from meta-analyses indicated favorable,
clinically relevant beneﬁt of CHM plus salmeterol on changes
in FEV1 (7 studies, pooled weighted mean differences (WMD)
= 0.20 L, 95% conﬁdence interval (CI): 0.06 to 0.34 L), changes
in the St George’s Respiratory Questionnaire scoring (SGRQ) (5
studies, pooled WMD = -4.99, 95% CI: -7.73 to -2.24). Improve-
ment on the 6-MinuteWalk Test (3 studies, pooledWMD= 32.8
meters, 95% CI: 18.3 to 47.4 meters) was also observed but the
magnitude of effect was clinically insigniﬁcant.
Conclusion: Results from NMA showed no differences
on the comparative effectiveness among CHM formula-
tions for improving FEV1. For SGRQ, NMA suggested that
Runfeijianpibushen Formula and Renshenbufei performed
best. Astragalusmembranaceus, Rehmanniae radixpreparata,
Radix codonopsisand root bark of Paeonia suffruticosa
Andr are the most commonly used herbs. Well conducted,
adequately powered trials are needed to conﬁrm their effec-
tiveness in the future.
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Clinical trials on herbal remedies in children:
a systematic review
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Purpose: Herbal remedies are very popular for self-
medication in minor diseases, also in children. However, in
Germany, the use of most herbal remedies not authorized
for this group, due to missing data on safety and efﬁcacy. A
systematic overview on clinical trials with herbal remedies
children does not exist so far.
Methods: A systematic search in medicinal databases on
herbal remedies in clinical trials with childrenwas performed,
and a database structured in 5 main categories (countries,
study design, age of the participants, indications, medicinal
herbal drugs) was established.
Results: Altogether 133 clinical trials with herbal reme-
dies in children were identiﬁed; 63% were conducted in only
5 countries (China (n=37), Germany (n=19), USA (n=12), Rus-
sia (n=12) and Great Britain (n=4)). 67.7% of the trials were
randomized, 32.2% double-blind. They were performed most
often in the age cohort 6-12 years (39.0%). Main indications
were: respiratory (n=26), gastro-intestinal (n=18) or neuropsy-
chiatric diseases (n=18) and skin problems (n=11). A large
variety of herbal drugs was tested, only with Hedera helix,
Pelargoniumsidoides, andVacciniummacrocarponmore than
3 trials had been conducted.
Conclusion: In children until now efﬁcacy and safety could
be demonstrated only for a few herbal remedies. The results
of the review however conﬁrm longstanding empirical knowl-
edge. As herbal remedies are often used because of their
assumedhigh potential of safety compared to synthetic drugs,
their efﬁcacy should be proven in clinical trials in order to
allow their broader application in this sensitive age-group.
Contact: Karin Kraft, karin.kraft@med.uni-rostock.de
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